Recent News

NCI grants to bolster UNC Lineberger’s work to address cancer disparities

NCI grants to bolster UNC Lineberger’s work to address cancer disparities

UNC Lineberger was awarded a grant with the Medical University of South Carolina Hollings Cancer Center to support a collaborative effort to address disparities in cancer incidence and death across North and South Carolina and Tennessee. In addition, the cancer center has received a grant to support the work of a community health educator to enhance outreach and education, and to disseminate culturally-appropriate, evidence-based cancer information in North Carolina.

NCI grants to bolster UNC Lineberger’s work to address cancer disparities - Read More…

Preclinical study finds no benefit for diabetes drug in pancreatic cancer

Preclinical study finds no benefit for diabetes drug in pancreatic cancer

UNC Lineberger researchers found in a study published in PLOS ONE that the diabetes drug metformin failed to show any benefit against pancreatic cancer, despite excitement about the drug for potential anti-cancer benefits. They believe the study shows the importance of testing new therapies in preclinical animal models that incorporate actual tumor tissue to better predict patient response.

Preclinical study finds no benefit for diabetes drug in pancreatic cancer - Read More…

From Pastor to Patient: Shay Greene

From Pastor to Patient: Shay Greene

After years of providing spiritual guidance and counseling to UNC patients, many of whom had cancer, the tables turned on hospital chaplain Shay Greene. On Sept. 16, 2011, she was diagnosed with Stage 3 breast cancer. Following a mastectomy, radiation, chemo and breast reconstruction, Greene says she was changed forever. Here, she tells the story of how a pen and paper became the tools that helped her move forward in her own faith and renewed her ministry to others who are going through cancer.

From Pastor to Patient: Shay Greene - Read More…

UNC Lineberger researchers uncover promising direction for the treatment of pancreatic cancers driven by KRAS mutation

UNC Lineberger researchers uncover promising direction for the treatment of pancreatic cancers driven by KRAS mutation

In the journal Cancer Cell, UNC Lineberger researchers report findings of a promising strategy to treat KRAS-mutant pancreatic cancers. Preclinical studies showed promise for using a type of investigational drug that works by inhibiting the protein ERK, the last of a series of signals of a signaling pathway that drives drive abnormal growth of cells with KRAS mutations.

UNC Lineberger researchers uncover promising direction for the treatment of pancreatic cancers driven by KRAS mutation - Read More…